Convalescent plasma: possible therapy for novel coronavirus disease 2019

Cao, Huiling; Shi, Yuan

doi:10.1111/trf.15797

Cited by 27 publications

(21 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This treatment refers to plasma therapy based on plasma or plasma derivatives, obtained from donors who were previously infected and have developed antibodies. This plasma/derivative is, in its turn, transfused into individuals with acute SARS-CoV-2 infection (Garraud, 2017;Cao and Shi, 2020). Even though the mechanism of action of convalescent plasma therapy is not fully understood, it presented great results in the treatment of patients with SARS during the SARS-CoV outbreak in Hong Kong in the early 2000s (Cheng et al, 2005).…”

Section: Ongoing Clinical Evaluations With Candidate Drugs Against Samentioning

confidence: 99%

Antivirals Against Coronaviruses: Candidate Drugs for SARS-CoV-2 Treatment?

et al. 2020

View full text Add to dashboard Cite

Coronaviruses (CoVs) are a group of viruses from the family Coronaviridae that can infect humans and animals, causing mild to severe diseases. The ongoing pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) represents a global threat, urging the development of new therapeutic strategies. Here we present a selection of relevant compounds that have been described from 2005 until now as having in vitro and/or in vivo antiviral activities against human and/or animal CoVs. We also present compounds that have reached clinical trials as well as further discussing the potentiality of other molecules for application in (re)emergent CoVs outbreaks. Finally, through rationalization of the data presented herein, we wish to encourage further research encompassing these compounds as potential SARS-CoV-2 drug candidates.

show abstract

Section: Ongoing Clinical Evaluations With Candidate Drugs Against Samentioning

confidence: 99%

Antivirals Against Coronaviruses: Candidate Drugs for SARS-CoV-2 Treatment?

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The use of convalescent plasma, a strategy of passive immunization that has been applied in the prevention and treatment of epidemic infections for more than 100 years [1], has been proposed and performed also during the recent COVID-19 pandemic [2]. Generally the convalescent plasma use during the Spanish influenza A (H1N1) pneumonia (pandemic of 1918-1920) has been reported as its first application [3][4][5][6]. In fact, several studies conducted during this pandemic suggested that the convalescent plasma could be effective in reducing mortality risk, as later confirmed by the meta-analysis carried out by Luke et al in 2006 [7], involving overall 1,703 patients from 8 suitable reports.…”

Section: The True Historical Origin Of Convalescent Plasma Therapymentioning

confidence: 99%

The true historical origin of convalescent plasma therapy

Marson¹,

Cozza²,

Silvestro³

2020

Transfusion and Apheresis Science

View full text Add to dashboard Cite

“…The emergence of SARS-CoV-2, the cause of COVID-19, has resulted in intense efforts to identify new and effective treatments. The lack of proven effective anti-viral therapies against coronaviruses has led to the broad utilization of COVID-19 convalescent plasma (CCP) obtained from survivors of COVID-19 to treat patients with active disease 1-3 . While the mechanism of action of CCP is uncertain, the most prevalent hypothesis is that CCP contains neutralizing antibodies that limit viral spread and replication 4 .…”

Section: Introductionmentioning

confidence: 99%

Exponential increase in neutralizing and spike specific antibodies following vaccination of COVID-19 convalescent plasma donors

Vickers

Sariol

Leon

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: With the recent approval of COVID-19 vaccines, recovered COVID-19 subjects who are vaccinated may be ideal candidates to donate COVID-19 convalescent plasma (CCP). Case Series: Three recovered COVID-19 patients were screened to donate CCP. All had molecularly confirmed COVID-19, and all were antibody positive by chemiluminescence immunoassay (DiaSorin) prior to vaccination. All were healthcare providers and were tested again for antibodies 11 to 21 days after they received the first dose of the vaccine (Pfizer). All showed dramatic increases (~50 fold) in spike-specific antibody levels and had at least a 20- fold increase in the IC50 neutralizing antibody titer based on plaque reduction neutralization testing (PRNT). The spike-specific antibody levels following vaccination were significantly higher than those seen in any non-vaccinated COVID-19 subjects tested to date at our facility. Conclusion: Spike-specific and neutralizing antibodies demonstrated dramatic increases following a single vaccination post COVID-19 infection which significantly exceeded values seen with COVID-19 infection alone. Recovered COVID-19 subjects who are vaccinated may make ideal candidates for CCP donation.

show abstract

Convalescent plasma: possible therapy for novel coronavirus disease 2019

Cited by 27 publications

References 29 publications

Antivirals Against Coronaviruses: Candidate Drugs for SARS-CoV-2 Treatment?

Antivirals Against Coronaviruses: Candidate Drugs for SARS-CoV-2 Treatment?

The true historical origin of convalescent plasma therapy

Exponential increase in neutralizing and spike specific antibodies following vaccination of COVID-19 convalescent plasma donors

Contact Info

Product

Resources

About